% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Neelsen:301714,
      author       = {C. J. O. Neelsen$^*$ and A. Mohammad$^*$ and H.-P.
                      Schlemmer$^*$ and A. Dimitrakopoulou-Strauss$^*$ and C.
                      Sachpekidis$^*$},
      title        = {{S}taging and treatment response assessment with
                      radiological and nuclear medicine approaches for
                      non-{H}odgkin lymphomas.[{S}taging und {T}herapieansprechen
                      mit radiologischen und nuklearmedizinischen {V}erfahren bei
                      {N}on-{H}odgkin-{L}ymphomen ({NHL})].},
      journal      = {Die Radiologie},
      volume       = {65},
      issn         = {2731-7048},
      address      = {[Berlin]},
      publisher    = {Springer Medizin Verlag GmbH},
      reportid     = {DKFZ-2025-01106},
      pages        = {508–517},
      year         = {2025},
      note         = {#EA:E010#LA:E060# / Volume 65, pages 508–517, (2025)},
      abstract     = {Non-Hodgkin lymphomas (NHL) represent a heterogeneous group
                      of malignant diseases in which the choice of imaging
                      modality and response criteria strongly depends on histology
                      and clinical context. Selecting the appropriate method is
                      essential for individualized treatment planning.According to
                      the Lugano classification, 18F‑fluorodeoxyglucose positron
                      emission tomography/computed tomography (18F‑FDG PET/CT)
                      is the reference standard for staging and response
                      assessment in 18F-FDG-avid NHL. For other lymphoma subtypes
                      with low or variable 18F-FDG avidity, or in cases where
                      reimbursement by statutory health insurance (GKV) is
                      lacking, contrast-enhanced CT is typically used.This article
                      discusses the new classification systems Lymphoma Response
                      to Immunomodulatory Therapy Criteria (LYRIC) and Response
                      Evaluation Criteria in Lymphoma (RECIL), as well as specific
                      features of certain lymphoma subtypes and novel imaging
                      approaches such as whole-body MRI and innovative PET
                      tracers.This narrative review does not include a systematic
                      evaluation of sensitivity or specificity data.In
                      18F-FDG-avid lymphomas 18F‑FDG PET/CT remains the gold
                      standard for precise staging and response assessment.Imaging
                      is essential for tailored therapy planning and monitoring in
                      NHL. As most NHL subtypes are 18FDG-avid, PET/CT is the
                      reference standard. However, contrast-enhanced CT continues
                      to play a significant role, particularly in Germany. New PET
                      tracers and whole-body MRI offer promising approaches but
                      require further studies and standardization.},
      subtyp        = {Review Article},
      keywords     = {Computed tomography (Other) / Diffuse large B‑cell
                      lymphoma (Other) / Positron emission tomography (Other) /
                      Response Evaluation Criteria in Lymphoma (Other) / Response
                      assessment (Other)},
      cin          = {E010 / E060},
      ddc          = {610},
      cid          = {I:(DE-He78)E010-20160331 / I:(DE-He78)E060-20160331},
      pnm          = {315 - Bildgebung und Radioonkologie (POF4-315)},
      pid          = {G:(DE-HGF)POF4-315},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {pmid:40434719},
      doi          = {10.1007/s00117-025-01459-5},
      url          = {https://inrepo02.dkfz.de/record/301714},
}